Breast and other cancer dormancy as a therapeutic endpoint: speculative recombinant T cell receptor ligand (RTL) adjuvant therapy worth considering?

PubWeight™: 0.76‹?›

🔗 View Article (PMC 2898695)

Published in BMC Cancer on June 02, 2010

Authors

Tibor Bakács1, Jitendra N Mehrishi

Author Affiliations

1: Department of Probability, Alfred Rényi Institute of Mathematics, Hungarian Academy of Sciences, Reáltanoda utca 13-15, H-1053 Budapest, Hungary.

Articles citing this

The benefits and harms of breast cancer screening: an independent review. Br J Cancer (2013) 3.43

Articles cited by this

Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer (2002) 17.49

The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev (1989) 13.15

Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst (2003) 11.27

Overdiagnosis in publicly organised mammography screening programmes: systematic review of incidence trends. BMJ (2009) 8.31

Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer (2007) 6.58

Seeding and propagation of untransformed mouse mammary cells in the lung. Science (2008) 5.33

Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res (2004) 4.48

A Gompertzian model of human breast cancer growth. Cancer Res (1988) 3.77

Advances in diagnostic imaging and overestimations of disease prevalence and the benefits of therapy. N Engl J Med (1993) 3.21

A novel doxycycline-inducible system for the transgenic analysis of mammary gland biology. FASEB J (2002) 3.05

Immune cells as mediators of solid tumor metastasis. Cancer Metastasis Rev (2008) 2.85

Overdiagnosis and overtreatment of breast cancer: overdiagnosis in randomised controlled trials of breast cancer screening. Breast Cancer Res (2005) 2.81

Premenopausal status accelerates relapse in node positive breast cancer: hypothesis links angiogenesis, screening controversy. Breast Cancer Res Treat (2001) 2.68

Cancer without disease. Nature (2004) 2.65

Local recurrences following mastectomy: support for the concept of tumor dormancy. J Natl Cancer Inst (1994) 2.34

Overdiagnosis and breast cancer screening. Breast Cancer Res (2005) 1.59

The effects of surgery on tumor growth: a century of investigations. Ann Oncol (2008) 1.59

Tumor cell dormancy: an NCI workshop report. Cancer Biol Ther (2007) 1.50

The law of mass action governs antigen-stimulated cytolytic activity of CD8+ cytotoxic T lymphocytes. Proc Natl Acad Sci U S A (1995) 1.43

Dormancy and surgery-driven escape from dormancy help explain some clinical features of breast cancer. APMIS (2008) 1.42

Breast cancer recurrence dynamics following adjuvant CMF is consistent with tumor dormancy and mastectomy-driven acceleration of the metastatic process. Ann Oncol (2005) 1.27

Toward a genetics of cancer resistance. Proc Natl Acad Sci U S A (2009) 1.25

Malignant melanoma in organ allograft recipients. Transplantation (1996) 1.22

Dormancy of metastatic melanoma. Pigment Cell Melanoma Res (2009) 1.19

Dormancy and breast cancer. J Surg Oncol (1990) 1.11

Seeding of epithelial cells into circulation during surgery for breast cancer: the fate of malignant and benign mobilized cells. World J Surg Oncol (2006) 1.08

Outgrowth of human liver metastases after resection of the primary colorectal tumor: a shift in the balance between apoptosis and proliferation. Int J Cancer (2006) 1.07

Cancer dormancy: from mice to man. Cell Cycle (2006) 0.92

Some aspects of the recombinantly expressed humanised superagonist anti-CD28 mAb, TGN1412 trial catastrophe lessons to safeguard mAbs and vaccine trials. Vaccine (2007) 0.91

Severity, time, and beta-adrenergic receptor involvement in surgery-induced immune alterations. J Surg Res (1998) 0.90

Liver regeneration and tumor stimulation--a review of cytokine and angiogenic factors. J Gastrointest Surg (2008) 0.89

Hypothesis: primary antiangiogenic method proposed to treat early stage breast cancer. BMC Cancer (2009) 0.89

Systemic immunomodulation of autoimmune disease using MHC-derived recombinant TCR ligands. Curr Drug Targets Inflamm Allergy (2005) 0.87

Cell surface profiling with peptide libraries yields ligand arrays that classify breast tumor subtypes. Mol Cancer Ther (2009) 0.81

Laparoscopic surgery for cancer: historical, theoretical, and technical considerations. Oncology (Williston Park) (2006) 0.80

Alterations in p53-specific T cells and other lymphocyte subsets in breast cancer patients during vaccination with p53-peptide loaded dendritic cells and low-dose interleukin-2. Vaccine (2008) 0.79

T cells survey the stability of the self: a testable hypothesis on the homeostatic role of TCR-MHC interactions. Int Arch Allergy Immunol (2007) 0.76